Stockreport
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks [Seeking Alpha]
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead's growth is increasingly concentrated in its HIV franchise, now nearly three-quarters of product revenue, raising dependency and concentration risks. Recent M&A activity, including the $7.8B Arcellx and $1.675B Ouro deals, aims to diversify, but their impact on revenue remains uncertain. I have exited my position due to demanding valuations and lack of diversified growth, despite strong dividend payouts and manageable leverage. Looking for more investing ideas like this one? Get them exclusively at Value In Corporate Events. Learn More » Michael Vi/iStock Editorial via Getty Images Shares of Gilead Sciences ( GILD ) have been on a major run higher in recent years, far outperforming many peers that have been struggling. This made sense, as Gilead traded at very low valuations from the More on my IG service If you like to see more ideas, please subscribe to the Investing Group "Value in Corporate Events" here and try the free trial. In this service we cover major e
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | GILD | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
GILD alerts
GILD alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
NEWS
NEWS
- A Look At Gilead Sciences (GILD) Valuation After Recent Mixed Share Price Performance [Yahoo! Finance][Yahoo! Finance]
- Gilead Extends Tender Offer to Acquire Arcellx[Business Wire]
- Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? [Yahoo! Finance][Yahoo! Finance]
- Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) [Seeking Alpha][Seeking Alpha]
- Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline [Yahoo! Finance][Yahoo! Finance]
- More
GILD
SEC Filings
SEC Filings
- 3/30/26 - Form 4
- 3/27/26 - Form 144
- 3/26/26 - Form SCHEDULE
- GILD's page on the SEC website
- More